[
  {
    "ts": "2025-11-07T08:24:10+00:00",
    "headline": "Lilly, Novo to Lower Obesity Drug Prices in Trump Deal",
    "summary": "The deals, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to more people on Medicare, the government health plan for older Americans.  “It’s a triumph for American patients that will save lives and improve the health of millions and millions of Americans,” Trump told reporters in the Oval Office.",
    "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "98cbc297-7e95-3688-8125-f7955e8a77c7",
      "content": {
        "id": "98cbc297-7e95-3688-8125-f7955e8a77c7",
        "contentType": "STORY",
        "title": "Lilly, Novo to Lower Obesity Drug Prices in Trump Deal",
        "description": "",
        "summary": "The deals, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to more people on Medicare, the government health plan for older Americans.  “It’s a triumph for American patients that will save lives and improve the health of millions and millions of Americans,” Trump told reporters in the Oval Office.",
        "pubDate": "2025-11-07T08:24:10Z",
        "displayTime": "2025-11-07T08:24:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gCZCsUJlU_eGSKICIOeYWw--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WHyHD1H6zLz3nNV.CBM0Ug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T13:20:10+00:00",
    "headline": "Novo Nordisk shares fall after Trump deal to slash obesity drug prices",
    "summary": "<body><p>STORY: Novo Nordisk shares fell as much as 3% on Friday (November 7) before scaling back.</p><p>Investors sold off after the Danish drugmaker and U.S. rival Eli Lilly announced a pricing deal with the U.S. government on Thursday (November 6).</p><p>They have agreed to lower prices of their popular weight-loss drugs, including Novo's Wegovy and Lilly's Zepbound.</p><p>It should lower monthly prices for cash payers and U.S. government programs like Medicare and Medicaid.</p><p>It reduces the prices to between $149 and $350, down from its current $500 to $1,000.</p><p>The deal also gives the companies a three-year relief from tariffs.</p><p>Analysts expect the price cuts to hit short-term revenue, but potentially boost volumes long term.</p><p>It come as Novo faces growing competition in the weight-loss drug market, where Lilly's Zepbound and copycat drugs have gained ground.</p><p>Novo was first to market when it launched Wegovy four years ago, and briefly became Europe's most valuable listed company as demand boomed.</p><p>But its market value has plunged 70% since last year due to supply constraints and commercial challenges.</p><p>Novo said the lower prices would have a negative \"low single-digit\" impact on global sales growth next year.</p><p>It added bigger volumes under Medicare were expected in the mid- to long term.</p></body>",
    "url": "https://finance.yahoo.com/video/novo-nordisk-shares-fall-trump-132010110.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "8fe8de81-7511-3be8-adce-27d28ae70973",
      "content": {
        "id": "8fe8de81-7511-3be8-adce-27d28ae70973",
        "contentType": "VIDEO",
        "title": "Novo Nordisk shares fall after Trump deal to slash obesity drug prices",
        "description": "<title><body><p>STORY: Novo Nordisk shares fell as much as 3% on Friday (November 7) before scaling back.</p><p>Investors sold off after the Danish drugmaker and U.S. rival Eli Lilly announced a pricing deal with the U.S. government on Thursday (November 6).</p><p>They have agreed to lower prices of their popular weight-loss drugs, including Novo's Wegovy and Lilly's Zepbound.</p><p>It should lower monthly prices for cash payers and U.S. government programs like Medicare and Medicaid.</p><p>It reduces the prices to between $149 and $350, down from its current $500 to $1,000.</p><p>The deal also gives the companies a three-year relief from tariffs.</p><p>Analysts expect the price cuts to hit short-term revenue, but potentially boost volumes long term.</p><p>It come as Novo faces growing competition in the weight-loss drug market, where Lilly's Zepbound and copycat drugs have gained ground.</p><p>Novo was first to market when it launched Wegovy four years ago, and briefly became Europe's most valuable listed company as demand boomed.</p><p>But its market value has plunged 70% since last year due to supply constraints and commercial challenges.</p><p>Novo said the lower prices would have a negative \"low single-digit\" impact on global sales growth next year.</p><p>It added bigger volumes under Medicare were expected in the mid- to long term.</p></body></title>",
        "summary": "<body><p>STORY: Novo Nordisk shares fell as much as 3% on Friday (November 7) before scaling back.</p><p>Investors sold off after the Danish drugmaker and U.S. rival Eli Lilly announced a pricing deal with the U.S. government on Thursday (November 6).</p><p>They have agreed to lower prices of their popular weight-loss drugs, including Novo's Wegovy and Lilly's Zepbound.</p><p>It should lower monthly prices for cash payers and U.S. government programs like Medicare and Medicaid.</p><p>It reduces the prices to between $149 and $350, down from its current $500 to $1,000.</p><p>The deal also gives the companies a three-year relief from tariffs.</p><p>Analysts expect the price cuts to hit short-term revenue, but potentially boost volumes long term.</p><p>It come as Novo faces growing competition in the weight-loss drug market, where Lilly's Zepbound and copycat drugs have gained ground.</p><p>Novo was first to market when it launched Wegovy four years ago, and briefly became Europe's most valuable listed company as demand boomed.</p><p>But its market value has plunged 70% since last year due to supply constraints and commercial challenges.</p><p>Novo said the lower prices would have a negative \"low single-digit\" impact on global sales growth next year.</p><p>It added bigger volumes under Medicare were expected in the mid- to long term.</p></body>",
        "pubDate": "2025-11-07T13:20:10Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/o8CgzY9MmXdqQ_d11jDkkg--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/a3f7e097-4757-4e75-9b17-c5bb9e02b14c/main/1280x720/39s232ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/e5I50W4c3KNvogpOtCVX_A--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/a3f7e097-4757-4e75-9b17-c5bb9e02b14c/main/1280x720/39s232ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6lcMJZ0kDdeps.e3DPuuGQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/a3f7e097-4757-4e75-9b17-c5bb9e02b14c/main/1280x720/39s232ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisk-shares-fall-trump-132010110.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/novo-nordisk-shares-fall-trump-132010110.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T13:13:25+00:00",
    "headline": "Pfizer and Novo Nordisk Face Off in $10 Billion Battle for Metsera",
    "summary": "Pharma rivals fight for control of next-generation obesity drug maker",
    "url": "https://finance.yahoo.com/news/pfizer-novo-nordisk-face-off-131325522.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "b0d2ea74-93d3-36b9-852b-e641b9f775f6",
      "content": {
        "id": "b0d2ea74-93d3-36b9-852b-e641b9f775f6",
        "contentType": "STORY",
        "title": "Pfizer and Novo Nordisk Face Off in $10 Billion Battle for Metsera",
        "description": "",
        "summary": "Pharma rivals fight for control of next-generation obesity drug maker",
        "pubDate": "2025-11-07T13:13:25Z",
        "displayTime": "2025-11-07T13:13:25Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vu.kxzmN7yCA.wz8Cs.cHg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Brb0J12XOUXl4lathAg3vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/08081c8c254eb269c81ba8feeb03a4b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-novo-nordisk-face-off-131325522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-novo-nordisk-face-off-131325522.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T13:00:03+00:00",
    "headline": "The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.",
    "summary": "Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the party over?",
    "url": "https://www.investors.com/news/technology/weight-loss-drugs-stocks-obesity-treatments-slump/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "f7b1bb3f-913e-3ed2-b14a-a511102acf42",
      "content": {
        "id": "f7b1bb3f-913e-3ed2-b14a-a511102acf42",
        "contentType": "STORY",
        "title": "The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things.",
        "description": "",
        "summary": "Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the party over?",
        "pubDate": "2025-11-07T13:00:03Z",
        "displayTime": "2025-11-07T13:00:03Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/f7b1bb3f-913e-3ed2-b14a-a511102acf42/the-weight-loss-drugs-craze.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/6957882acf125f3e690d774d013e61af",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TmIuGINDJ4jw.ePvaRQ6LA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/6957882acf125f3e690d774d013e61af.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/y0YPyPni.dhRliRbMw0.7g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/6957882acf125f3e690d774d013e61af.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/weight-loss-drugs-stocks-obesity-treatments-slump/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T13:00:00+00:00",
    "headline": "Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors",
    "summary": "Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS therapies, today announced the appointment of Laurent Fischer, MD, as its first independent Chair of the Board of Directors, alongside the company's first data presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place in National Harbor, MD from November 5-9, 2025. These milestones collectively reflect Shinobi's continued momentum as it advances its oncology and autoimmun",
    "url": "https://finance.yahoo.com/news/shinobi-therapeutics-announces-appointment-dr-130000570.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "3324746f-1aeb-39cd-909f-223ba9c40f48",
      "content": {
        "id": "3324746f-1aeb-39cd-909f-223ba9c40f48",
        "contentType": "STORY",
        "title": "Shinobi Therapeutics Announces the Appointment of Dr. Laurent Fischer as Chair of its Board of Directors",
        "description": "",
        "summary": "Shinobi Therapeutics, the biotechnology company developing a new class of immune evasive iPS therapies, today announced the appointment of Laurent Fischer, MD, as its first independent Chair of the Board of Directors, alongside the company's first data presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place in National Harbor, MD from November 5-9, 2025. These milestones collectively reflect Shinobi's continued momentum as it advances its oncology and autoimmun",
        "pubDate": "2025-11-07T13:00:00Z",
        "displayTime": "2025-11-07T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/81ee5f9e49c39ec93a4ee9c510e463df",
          "originalWidth": 400,
          "originalHeight": 80,
          "caption": "Shinobi Therapeutics Logo (PRNewsfoto/Shinobi Therapeutics)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Min4p_Dlrjjs1BK_f1xcug--~B/aD04MDt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/81ee5f9e49c39ec93a4ee9c510e463df.cf.webp",
              "width": 400,
              "height": 80,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hg7Q8bl37_M8BfQOvq8Rig--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/81ee5f9e49c39ec93a4ee9c510e463df.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/shinobi-therapeutics-announces-appointment-dr-130000570.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/shinobi-therapeutics-announces-appointment-dr-130000570.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ADVM"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T12:42:37+00:00",
    "headline": "Eli Lilly and Novo Nordisk Agree to Cut Weight-Loss Drug Prices in U.S. Deal",
    "summary": "Partnership with Trump administration aims to expand Medicare and Medicaid access",
    "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-agree-124237615.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "3e802e37-f866-3d8d-a332-a2b817a21dbd",
      "content": {
        "id": "3e802e37-f866-3d8d-a332-a2b817a21dbd",
        "contentType": "STORY",
        "title": "Eli Lilly and Novo Nordisk Agree to Cut Weight-Loss Drug Prices in U.S. Deal",
        "description": "",
        "summary": "Partnership with Trump administration aims to expand Medicare and Medicaid access",
        "pubDate": "2025-11-07T12:42:37Z",
        "displayTime": "2025-11-07T12:42:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c",
          "originalWidth": 500,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8b14zxH4BANQFraIfqB7ug--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 500,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j_oIKXponyFLhltsjvcwTQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/d0b2925021ba921981c34cbf188ac66c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-agree-124237615.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-agree-124237615.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T12:40:19+00:00",
    "headline": "Lilly to advance alternative obesity candidate to Phase III",
    "summary": "This update comes at a time when rivalries in the obesity market are heating up.",
    "url": "https://www.clinicaltrialsarena.com/news/lilly-to-advance-alternative-obesity-candidate-to-phase-iii/",
    "source": "Clinical Trials Arena",
    "provider": "yfinance",
    "raw": {
      "id": "11db5f56-03c3-3bb0-bd03-7e19eab7e649",
      "content": {
        "id": "11db5f56-03c3-3bb0-bd03-7e19eab7e649",
        "contentType": "STORY",
        "title": "Lilly to advance alternative obesity candidate to Phase III",
        "description": "",
        "summary": "This update comes at a time when rivalries in the obesity market are heating up.",
        "pubDate": "2025-11-07T12:40:19Z",
        "displayTime": "2025-11-07T12:40:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/clinical_trials_arena_396/27684e2ec96285a0aab3f4da3f57305b",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "Eli Lilly will advance eloralintide to Phase III trials in obesity. Image credit: Michael Vi / Shutterstock.com",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KAJNRGUFgUFa5CcTKOkZqg--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/27684e2ec96285a0aab3f4da3f57305b.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8Mpux0tCUYWz6qak2DPo6w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/clinical_trials_arena_396/27684e2ec96285a0aab3f4da3f57305b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Clinical Trials Arena",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.clinicaltrialsarena.com/news/lilly-to-advance-alternative-obesity-candidate-to-phase-iii/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-advance-alternative-obesity-candidate-124019747.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T12:03:03+00:00",
    "headline": "Novo shares fall after weight-loss drug price deal",
    "summary": "Investing.com -- Shares of Novo Nordisk are down 2.5% on Friday after the Trump administration announced agreements with the Danish drugmaker and Eli Lilly to cut prices for GLP-1 drugs used to treat diabetes and obesity.",
    "url": "https://finance.yahoo.com/news/novo-shares-fall-weight-loss-120303221.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "bd15d7c2-fe90-3c12-a06b-94a658bdda66",
      "content": {
        "id": "bd15d7c2-fe90-3c12-a06b-94a658bdda66",
        "contentType": "STORY",
        "title": "Novo shares fall after weight-loss drug price deal",
        "description": "",
        "summary": "Investing.com -- Shares of Novo Nordisk are down 2.5% on Friday after the Trump administration announced agreements with the Danish drugmaker and Eli Lilly to cut prices for GLP-1 drugs used to treat diabetes and obesity.",
        "pubDate": "2025-11-07T12:03:03Z",
        "displayTime": "2025-11-07T12:03:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-shares-fall-weight-loss-120303221.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-shares-fall-weight-loss-120303221.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T11:49:00+00:00",
    "headline": "Health Care Roundup: Market Talk",
    "summary": "Find insight on Novo Nordisk, AstraZeneca, Hikma Pharmaceuticals in the latest Market Talks covering the Health Care sector.",
    "url": "https://www.wsj.com/health/health-care-roundup-market-talk-9f24289f?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "7514cada-a666-3ab9-ab0c-316e1ea46340",
      "content": {
        "id": "7514cada-a666-3ab9-ab0c-316e1ea46340",
        "contentType": "STORY",
        "title": "Health Care Roundup: Market Talk",
        "description": "",
        "summary": "Find insight on Novo Nordisk, AstraZeneca, Hikma Pharmaceuticals in the latest Market Talks covering the Health Care sector.",
        "pubDate": "2025-11-07T11:49:00Z",
        "displayTime": "2025-11-07T11:49:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/7514cada-a666-3ab9-ab0c-316e1ea46340/health-care-roundup-market.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/925d50bc392450866d0e31a31851fbad",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MazWkMwra25uqkZRdtaNLA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/925d50bc392450866d0e31a31851fbad.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_RYuDsxuMP_RlRIfTmZJBQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/925d50bc392450866d0e31a31851fbad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/health-care-roundup-market-talk-9f24289f?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]